Kevin J. J. Kwinten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kevin J. J. Kwinten has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Nicoline Hoogerbrugge
Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
4 shared publicationsAnne M. van Altena
Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands
3 shared publicationsJoanne A. de Hullu
Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands
3 shared publicationsAnne M van Altena
Department of Obstetrics & Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publicationsERN GENTURIS Survey Group
2 shared publicationsJoanne A de Hullu
Department of Obstetrics & Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by Springer Nature in Familial Cancer
- Vol. 25 (2)
Correction: Hereditary gynecological cancer management in women with Lynch syndrome: a survey across Europe
- 22 April 2026
- Published by Springer Nature in Familial Cancer
- Vol. 25 (2)
Open AccessCorrection: Hereditary gynecological cancer management in women with Lynch syndrome: a survey across Europe
- Open Access
- 31 March 2026
- Published by Springer Nature in Familial Cancer
- Vol. 25 (2)
Hereditary gynecological cancer management in women with Lynch syndrome: a survey across Europe
We aim to compare clinical practices in the gynecological management of women with Lynch syndrome across Europe and assess the need for multidisciplinary gynecological care for this high-risk population. European gynecologists involved in the clinical care of women with Lynch syndrome were invited to complete a cross-sectional survey regarding their clinical practices and organization of care. All participating gynecologists were based in hospitals that are members of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS). A total of 33 gynecologists (57%) from 25 unique hospitals across 12 countries participated in the survey. National guidelines on the gynecological management of women with Lynch syndrome were absent in a significant number of European countries. Local multidisciplinary team meetings were available in 61% of hospitals. Considerable heterogeneity was reported in the organization of care, as well as in surveillance, prevention, and treatment strategies. Standardized European guidelines for the gynecological care of women with Lynch syndrome are warranted to promote uniformity. Gynecologists specialized in hereditary cancer should take the lead in developing and implementing these guidelines. Hospitals managing women with Lynch syndrome should have the resources to organize multidisciplinary team meetings, which are crucial for the effective implementation of these guidelines and the improvement of personalized care.
- 31 March 2026
- Published by Springer Nature in Familial Cancer
- Vol. 25 (2)
Open AccessHereditary gynecological cancer management in women with Lynch syndrome: a survey across Europe
We aim to compare clinical practices in the gynecological management of women with Lynch syndrome across Europe and assess the need for multidisciplinary gynecological care for this high-risk population. European gynecologists involved in the clinical care of women with Lynch syndrome were invited to complete a cross-sectional survey regarding their clinical practices and organization of care. All participating gynecologists were based in hospitals that are members of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS). A total of 33 gynecologists (57%) from 25 unique hospitals across 12 countries participated in the survey. National guidelines on the gynecological management of women with Lynch syndrome were absent in a significant number of European countries. Local multidisciplinary team meetings were available in 61% of hospitals. Considerable heterogeneity was reported in the organization of care, as well as in surveillance, prevention, and treatment strategies. Standardized European guidelines for the gynecological care of women with Lynch syndrome are warranted to promote uniformity. Gynecologists specialized in hereditary cancer should take the lead in developing and implementing these guidelines. Hospitals managing women with Lynch syndrome should have the resources to organize multidisciplinary team meetings, which are crucial for the effective implementation of these guidelines and the improvement of personalized care.
- Open Access
- 24 March 2026
- Published by Springer Nature in Familial Cancer
- Vol. 25 (2) , 33
Prevention strategies for hereditary gynaecological cancer in Lynch syndrome
Lynch syndrome is a hereditary cancer predisposition condition associated with an elevated lifetime risk of colorectal, endometrial, ovarian, and several other malignancies. This review provides an updated overview of evidence-based prevention strategies for gynaecological cancers in patients with Lynch syndrome. Risk-reducing hysterectomy with bilateral salpingo-oophorectomy is the most effective intervention for lowering cancer incidence and mortality, but is associated with surgical morbidity and requires careful consideration of reproductive plans and the adverse consequences of premature menopause. Gynaecological surveillance using transvaginal ultrasound and endometrial biopsy is widely implemented as an alternative; however, available evidence is heterogeneous and indicates no benefit in reducing mortality. Novel approaches—such as biomarker-based detection using DNA methylation analysis of cervicovaginal samples, liquid biopsy techniques, and microbiome profiling—offer promising, non-invasive alternatives but require prospective validation in Lynch-specific populations. Chemoprevention with hormonal agents and aspirin may reduce cancer risk, while vaccine-based prevention strategies are under active investigation. Adoption of a healthy lifestyle is recommended for overall health, although its impact on gynaecological cancer risk in Lynch syndrome remains uncertain. Future research should prioritise prospective trials to establish optimal cancer prevention protocols, validate novel biomarkers and preventive cancer vaccine strategies, and evaluate the long-term effectiveness, acceptability, and cost-effectiveness of combined preventive approaches to improve outcomes in this high hereditary-risk population.
- 24 March 2026
- Published by Springer Nature in Familial Cancer
- Vol. 25 (2) , 33
Open AccessPrevention strategies for hereditary gynaecological cancer in Lynch syndrome
Lynch syndrome is a hereditary cancer predisposition condition associated with an elevated lifetime risk of colorectal, endometrial, ovarian, and several other malignancies. This review provides an updated overview of evidence-based prevention strategies for gynaecological cancers in patients with Lynch syndrome. Risk-reducing hysterectomy with bilateral salpingo-oophorectomy is the most effective intervention for lowering cancer incidence and mortality, but is associated with surgical morbidity and requires careful consideration of reproductive plans and the adverse consequences of premature menopause. Gynaecological surveillance using transvaginal ultrasound and endometrial biopsy is widely implemented as an alternative; however, available evidence is heterogeneous and indicates no benefit in reducing mortality. Novel approaches—such as biomarker-based detection using DNA methylation analysis of cervicovaginal samples, liquid biopsy techniques, and microbiome profiling—offer promising, non-invasive alternatives but require prospective validation in Lynch-specific populations. Chemoprevention with hormonal agents and aspirin may reduce cancer risk, while vaccine-based prevention strategies are under active investigation. Adoption of a healthy lifestyle is recommended for overall health, although its impact on gynaecological cancer risk in Lynch syndrome remains uncertain. Future research should prioritise prospective trials to establish optimal cancer prevention protocols, validate novel biomarkers and preventive cancer vaccine strategies, and evaluate the long-term effectiveness, acceptability, and cost-effectiveness of combined preventive approaches to improve outcomes in this high hereditary-risk population.
- Open Access
- 19 July 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (14) , e70000
Cervicovaginal specimen biomarkers for early detection of ovarian and endometrial cancer: A review
Background: In the last decade, technical innovations have resulted in the development of several minimally invasive diagnostic cancer tools. Within women at high risk of developing ovarian cancer (OC) or endometrial cancer (EC) due to a hereditary cancer syndrome, there is an urgent need for minimally invasive and patient‐friendly methods to detect OC and EC at an early stage.Materials and Methods: We performed a systematic search of studies using DNA methylation or mutation analysis, microbiome, or proteomics performed on cervicovaginal specimens (smear, swab, or tampon) intended to detect OC and EC published until January 2024.Results: Included studies (n = 36) showed high heterogeneity in terms of biomarkers used and outcomes, and only a few studies reported on the detection of biomarkers in high‐risk subgroups.Conclusion: Based on the findings in this review, DNA methylation techniques seem to be the most promising for detecting OC and EC at early stages in the general population. Future validation of cervicovaginal DNA methylation techniques is needed to determine whether this technique might be beneficial in hereditary high‐risk subgroups.
- 19 July 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (14) , e70000
Open AccessCervicovaginal specimen biomarkers for early detection of ovarian and endometrial cancer: A review
Background: In the last decade, technical innovations have resulted in the development of several minimally invasive diagnostic cancer tools. Within women at high risk of developing ovarian cancer (OC) or endometrial cancer (EC) due to a hereditary cancer syndrome, there is an urgent need for minimally invasive and patient‐friendly methods to detect OC and EC at an early stage.Materials and Methods: We performed a systematic search of studies using DNA methylation or mutation analysis, microbiome, or proteomics performed on cervicovaginal specimens (smear, swab, or tampon) intended to detect OC and EC published until January 2024.Results: Included studies (n = 36) showed high heterogeneity in terms of biomarkers used and outcomes, and only a few studies reported on the detection of biomarkers in high‐risk subgroups.Conclusion: Based on the findings in this review, DNA methylation techniques seem to be the most promising for detecting OC and EC at early stages in the general population. Future validation of cervicovaginal DNA methylation techniques is needed to determine whether this technique might be beneficial in hereditary high‐risk subgroups.
- Open Access
- 10 May 2023
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 66 (7) , 104785
Yield of annual endometrial cancer surveillance in women with PTEN Hamartoma Tumor Syndrome
- 10 May 2023
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 66 (7) , 104785
Open AccessYield of annual endometrial cancer surveillance in women with PTEN Hamartoma Tumor Syndrome